A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Shun Lu, MD
Shanghai Chest Hospital, Shanghai, China
Principal Investigator - Suresh S Ramalingam, MD
Emory University School of Medicine, Atlanta, U.S.
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
118 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Ciudad Autónoma de Bs. As., Argentina
- Research Site
Ciudad Autónoma de Bs. As., Argentina
- Research Site
Mar del Plata, Argentina
- Research Site
Rosario, Argentina
- Research Site
San Salvador de Jujuy, Argentina
- Research Site
Barretos, Brazil
- Research Site
Curitiba, Brazil
- Research Site
Florianópolis, Brazil
- Research Site
Fortaleza, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Ribeirão Preto, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
Beijing, China
- Research Site
Beijing, China
- Research Site
Changchun, China
- Research Site
Changsha, China
- Research Site
Chengdu, China
- Research Site
Guangzhou, China
- Research Site
Hangzhou, China
- Research Site
Hangzhou, China
- Research Site
Hangzhou, China
- Research Site
Jinan, China
- Research Site
Linhai, China
- Research Site
Shanghai, China
- Research Site
Shanghai, China
- Research Site
Wuhan, China
- Research Site
Wuhan, China
- Research Site
Ürümqi, China
- Research Site
Budapest, Hungary
- Research Site
Budapest, Hungary
- Research Site
Gyöngyös - Mátraháza, Hungary
- Research Site
Pécs, Hungary
- Research Site
Bangalore, India
- Research Site
Gurgaon, India
- Research Site
Hubli, India
- Research Site
Karamsad, India
- Research Site
Kolkata, India
- Research Site
Nashik, India
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Jul 2018
- Primary completion
- 5 Jan 2024
- Completion
- 29 Oct 2027
- Last update posted
- 5 May 2026
- Registered enrollment
- 216
- Registry id
- NCT03521154
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.